ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "AI Ablation Cuts Persistent AF Recurrence 11/17/25"
Episode Synopsis
Welcome to Cardiology Today – Recorded November 17, 2025. This episode summarizes 5 key cardiology studies on topics like selexipag and atrial flutter. Key takeaway: AI Ablation Cuts Persistent AF Recurrence.
Article Links:
Article 1: Evaluating oral selexipag in PAH: Insights on survival, safety and dosing patterns from the complete observation period of GRIPHON and its open-label extension. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 2: Molecular biopsy features associated with baseline lung allograft dysfunction in a multicenter international cohort. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 3: Pulmonary Artery Fresh Floating Thrombus in Patients with Chronic Thromboembolic Pulmonary Hypertension on Low-Dose Direct Oral Anticoagulants: A Single-Center Angiographic Observational Study. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 4: Targetable atrial tachycardias after artificial-intelligence-guided ablation of persistent atrial fibrillation. (Heart rhythm)
Article 5: Atrial Arrhythmia Recurrence After the Maze Procedure: Insights from Catheter-based Mapping. (Heart rhythm)
Full episode page: https://podcast.explainheart.com/podcast/ai-ablation-cuts-persistent-af-recurrence-11-17-25/
Featured Articles
Article 1: Evaluating oral selexipag in PAH: Insights on survival, safety and dosing patterns from the complete observation period of GRIPHON and its open-label extension.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41242357
Summary: The GRIPHON study found that oral selexipag, a prostacyclin receptor agonist, significantly reduced morbidity and mortality risk compared to placebo in patients with pulmonary arterial hypertension. Five-year survival estimates for pulmonary arterial hypertension patients in real-world clinical practice were 57 percent. The GRIPHON trial, along with its open-label extension, provided the longest follow-up to date for a pulmonary arterial hypertension trial. Complete results regarding the two main analysis sets were not available in this abstract.
Article 2: Molecular biopsy features associated with baseline lung allograft dysfunction in a multicenter international cohort.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41242356
Summary: This study examined molecular biopsy features associated with baseline lung allograft dysfunction in an international cohort of lung transplant recipients. Researchers investigated transbronchial biopsy gene expression changes linked to baseline lung allograft dysfunction. Baseline lung allograft dysfunction status was assessed at one-year post-transplant. Specific numerical or definitive results regarding the associations found were not provided in this abstract.
Article 3: Pulmonary Artery Fresh Floating Thrombus in Patients with Chronic Thromboembolic Pulmonary Hypertension on Low-Dose Direct Oral Anticoagulants: A Single-Center Angiographic Observational Study.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41242355
Summary: This observational study retrospectively analyzed 721 follow-up selective pulmonary angiograms from 239 patients with chronic thromboembolic pulmonary hypertension. All patients completed balloon pulmonary angioplasty and received long-term anticoagulation with low-dose direct oral anticoagulants, standard-dose direct oral anticoagulants, or vitamin K antagonists. The study evaluated baseline characteristics, follow-up outcomes, and the incidence of pulmonary artery fresh floating thrombus. Specific numerical findings regarding these outcomes and comparisons between the anticoagulant regimens were not provided in this abstract.
Article 4: Targetable atrial tachycardias after artificial-intelligence-guided ablation of persistent atrial fibrillation.
Journal: Heart rhythm
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41242590
Summary: The TAILORED-AF randomized trial demonstrated that artificial intelligence-guided ablation of spatio-temporal dispersion combined with pulmonary vein isolation significantly reduced atrial fibrillation recurrence at one-year follow-up in patients with persistent atrial fibrillation. Despite this, approximately one third of the patient population experienced atrial tachycardia recurrences. The study found that most of these atrial tachycardia recurrences were successfully ablated. This post-hoc analysis identified the exact mechanisms and locations of these targetable atrial tachycardias.
Article 5: Atrial Arrhythmia Recurrence After the Maze Procedure: Insights from Catheter-based Mapping.
Journal: Heart rhythm
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41242589
Summary: This study retrospectively analyzed 86 patients who experienced recurrent atrial arrhythmias after undergoing the Cox-Maze procedure between 2008 and 2023. These patients subsequently required endocardial catheter ablation for recurrent atrial fibrillation or atrial flutter. Electroanatomic mapping was employed to assess lesion integrity and characterize the mechanisms of these recurrent atrial arrhythmias. Specific findings regarding the types of mechanisms or lesion gaps observed were not provided in this abstract.
Transcript
Today’s date is November 17, 2025. Welcome to Cardiology Today. Here are the latest research findings.
Article number one. Evaluating oral selexipag in PAH: Insights on survival, safety and dosing patterns from the complete observation period of GRIPHON and its open-label extension. The GRIPHON study found that oral selexipag, a prostacyclin receptor agonist, significantly reduced morbidity and mortality risk compared to placebo in patients with pulmonary arterial hypertension. Five-year survival estimates for pulmonary arterial hypertension patients in real-world clinical practice were 57 percent. The GRIPHON trial, along with its open-label extension, provided the longest follow-up to date for a pulmonary arterial hypertension trial. Complete results regarding the two main analysis sets were not available in this abstract.
Article number two. Molecular biopsy features associated with baseline lung allograft dysfunction in a multicenter international cohort. This study examined molecular biopsy features associated with baseline lung allograft dysfunction in an international cohort of lung transplant recipients. Researchers investigated transbronchial biopsy gene expression changes linked to baseline lung allograft dysfunction. Baseline lung allograft dysfunction status was assessed at one-year post-transplant. Specific numerical or definitive results regarding the associations found were not provided in this abstract.
Article number three. Pulmonary Artery Fresh Floating Thrombus in Patients with Chronic Thromboembolic Pulmonary Hypertension on Low-Dose Direct Oral Anticoagulants: A Single-Center Angiographic Observational Study. This observational study retrospectively analyzed 721 follow-up selective pulmonary angiograms from 239 patients with chronic thromboembolic pulmonary hypertension. All patients completed balloon pulmonary angioplasty and received long-term anticoagulation with low-dose direct oral anticoagulants, standard-dose direct oral anticoagulants, or vitamin K antagonists. The study evaluated baseline characteristics, follow-up outcomes, and the incidence of pulmonary artery fresh floating thrombus. Specific numerical findings regarding these outcomes and comparisons between the anticoagulant regimens were not provided in this abstract.
Article number four. Targetable atrial tachycardias after artificial-intelligence-guided ablation of persistent atrial fibrillation. The TAILORED-AF randomized trial demonstrated that artificial intelligence-guided ablation of spatio-temporal dispersion combined with pulmonary vein isolation significantly reduced atrial fibrillation recurrence at one-year follow-up in patients with persistent atrial fibrillation. Despite this, approximately one third of the patient population experienced atrial tachycardia recurrences. The study found that most of these atrial tachycardia recurrences were successfully ablated. This post-hoc analysis identified the exact mechanisms and locations of these targetable atrial tachycardias.
Article number five. Atrial Arrhythmia Recurrence After the Maze Procedure: Insights from Catheter-based Mapping. This study retrospectively analyzed 86 patients who experienced recurrent atrial arrhythmias after undergoing the Cox-Maze procedure between 2008 and 2023. These patients subsequently required endocardial catheter ablation for recurrent atrial fibrillation or atrial flutter. Electroanatomic mapping was employed to assess lesion integrity and characterize the mechanisms of these recurrent atrial arrhythmias. Specific findings regarding the types of mechanisms or lesion gaps observed were not provided in this abstract.
Thank you for listening. Don’t forget to subscribe.
Keywords
selexipag, atrial flutter, direct oral anticoagulants, prostacyclin receptor agonist, mortality, pulmonary vein isolation, electroanatomic mapping, transbronchial biopsy, recurrent arrhythmia, lung transplant, vitamin K antagonists, pulmonary arterial hypertension, atrial tachycardia, GRIPHON trial, Cox-Maze procedure, morbidity, balloon pulmonary angioplasty, baseline lung allograft dysfunction, gene expression, atrial fibrillation, artificial intelligence, persistent atrial fibrillation, pulmonary angiogram, pulmonary function, chronic thromboembolic pulmonary hypertension, catheter ablation.
About
Concise summaries of cardiovascular research for professionals.
Subscribe • Share • FollowThe post AI Ablation Cuts Persistent AF Recurrence 11/17/25 first appeared on Cardiology Today.
Article Links:
Article 1: Evaluating oral selexipag in PAH: Insights on survival, safety and dosing patterns from the complete observation period of GRIPHON and its open-label extension. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 2: Molecular biopsy features associated with baseline lung allograft dysfunction in a multicenter international cohort. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 3: Pulmonary Artery Fresh Floating Thrombus in Patients with Chronic Thromboembolic Pulmonary Hypertension on Low-Dose Direct Oral Anticoagulants: A Single-Center Angiographic Observational Study. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 4: Targetable atrial tachycardias after artificial-intelligence-guided ablation of persistent atrial fibrillation. (Heart rhythm)
Article 5: Atrial Arrhythmia Recurrence After the Maze Procedure: Insights from Catheter-based Mapping. (Heart rhythm)
Full episode page: https://podcast.explainheart.com/podcast/ai-ablation-cuts-persistent-af-recurrence-11-17-25/
Featured Articles
Article 1: Evaluating oral selexipag in PAH: Insights on survival, safety and dosing patterns from the complete observation period of GRIPHON and its open-label extension.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41242357
Summary: The GRIPHON study found that oral selexipag, a prostacyclin receptor agonist, significantly reduced morbidity and mortality risk compared to placebo in patients with pulmonary arterial hypertension. Five-year survival estimates for pulmonary arterial hypertension patients in real-world clinical practice were 57 percent. The GRIPHON trial, along with its open-label extension, provided the longest follow-up to date for a pulmonary arterial hypertension trial. Complete results regarding the two main analysis sets were not available in this abstract.
Article 2: Molecular biopsy features associated with baseline lung allograft dysfunction in a multicenter international cohort.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41242356
Summary: This study examined molecular biopsy features associated with baseline lung allograft dysfunction in an international cohort of lung transplant recipients. Researchers investigated transbronchial biopsy gene expression changes linked to baseline lung allograft dysfunction. Baseline lung allograft dysfunction status was assessed at one-year post-transplant. Specific numerical or definitive results regarding the associations found were not provided in this abstract.
Article 3: Pulmonary Artery Fresh Floating Thrombus in Patients with Chronic Thromboembolic Pulmonary Hypertension on Low-Dose Direct Oral Anticoagulants: A Single-Center Angiographic Observational Study.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41242355
Summary: This observational study retrospectively analyzed 721 follow-up selective pulmonary angiograms from 239 patients with chronic thromboembolic pulmonary hypertension. All patients completed balloon pulmonary angioplasty and received long-term anticoagulation with low-dose direct oral anticoagulants, standard-dose direct oral anticoagulants, or vitamin K antagonists. The study evaluated baseline characteristics, follow-up outcomes, and the incidence of pulmonary artery fresh floating thrombus. Specific numerical findings regarding these outcomes and comparisons between the anticoagulant regimens were not provided in this abstract.
Article 4: Targetable atrial tachycardias after artificial-intelligence-guided ablation of persistent atrial fibrillation.
Journal: Heart rhythm
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41242590
Summary: The TAILORED-AF randomized trial demonstrated that artificial intelligence-guided ablation of spatio-temporal dispersion combined with pulmonary vein isolation significantly reduced atrial fibrillation recurrence at one-year follow-up in patients with persistent atrial fibrillation. Despite this, approximately one third of the patient population experienced atrial tachycardia recurrences. The study found that most of these atrial tachycardia recurrences were successfully ablated. This post-hoc analysis identified the exact mechanisms and locations of these targetable atrial tachycardias.
Article 5: Atrial Arrhythmia Recurrence After the Maze Procedure: Insights from Catheter-based Mapping.
Journal: Heart rhythm
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41242589
Summary: This study retrospectively analyzed 86 patients who experienced recurrent atrial arrhythmias after undergoing the Cox-Maze procedure between 2008 and 2023. These patients subsequently required endocardial catheter ablation for recurrent atrial fibrillation or atrial flutter. Electroanatomic mapping was employed to assess lesion integrity and characterize the mechanisms of these recurrent atrial arrhythmias. Specific findings regarding the types of mechanisms or lesion gaps observed were not provided in this abstract.
Transcript
Today’s date is November 17, 2025. Welcome to Cardiology Today. Here are the latest research findings.
Article number one. Evaluating oral selexipag in PAH: Insights on survival, safety and dosing patterns from the complete observation period of GRIPHON and its open-label extension. The GRIPHON study found that oral selexipag, a prostacyclin receptor agonist, significantly reduced morbidity and mortality risk compared to placebo in patients with pulmonary arterial hypertension. Five-year survival estimates for pulmonary arterial hypertension patients in real-world clinical practice were 57 percent. The GRIPHON trial, along with its open-label extension, provided the longest follow-up to date for a pulmonary arterial hypertension trial. Complete results regarding the two main analysis sets were not available in this abstract.
Article number two. Molecular biopsy features associated with baseline lung allograft dysfunction in a multicenter international cohort. This study examined molecular biopsy features associated with baseline lung allograft dysfunction in an international cohort of lung transplant recipients. Researchers investigated transbronchial biopsy gene expression changes linked to baseline lung allograft dysfunction. Baseline lung allograft dysfunction status was assessed at one-year post-transplant. Specific numerical or definitive results regarding the associations found were not provided in this abstract.
Article number three. Pulmonary Artery Fresh Floating Thrombus in Patients with Chronic Thromboembolic Pulmonary Hypertension on Low-Dose Direct Oral Anticoagulants: A Single-Center Angiographic Observational Study. This observational study retrospectively analyzed 721 follow-up selective pulmonary angiograms from 239 patients with chronic thromboembolic pulmonary hypertension. All patients completed balloon pulmonary angioplasty and received long-term anticoagulation with low-dose direct oral anticoagulants, standard-dose direct oral anticoagulants, or vitamin K antagonists. The study evaluated baseline characteristics, follow-up outcomes, and the incidence of pulmonary artery fresh floating thrombus. Specific numerical findings regarding these outcomes and comparisons between the anticoagulant regimens were not provided in this abstract.
Article number four. Targetable atrial tachycardias after artificial-intelligence-guided ablation of persistent atrial fibrillation. The TAILORED-AF randomized trial demonstrated that artificial intelligence-guided ablation of spatio-temporal dispersion combined with pulmonary vein isolation significantly reduced atrial fibrillation recurrence at one-year follow-up in patients with persistent atrial fibrillation. Despite this, approximately one third of the patient population experienced atrial tachycardia recurrences. The study found that most of these atrial tachycardia recurrences were successfully ablated. This post-hoc analysis identified the exact mechanisms and locations of these targetable atrial tachycardias.
Article number five. Atrial Arrhythmia Recurrence After the Maze Procedure: Insights from Catheter-based Mapping. This study retrospectively analyzed 86 patients who experienced recurrent atrial arrhythmias after undergoing the Cox-Maze procedure between 2008 and 2023. These patients subsequently required endocardial catheter ablation for recurrent atrial fibrillation or atrial flutter. Electroanatomic mapping was employed to assess lesion integrity and characterize the mechanisms of these recurrent atrial arrhythmias. Specific findings regarding the types of mechanisms or lesion gaps observed were not provided in this abstract.
Thank you for listening. Don’t forget to subscribe.
Keywords
selexipag, atrial flutter, direct oral anticoagulants, prostacyclin receptor agonist, mortality, pulmonary vein isolation, electroanatomic mapping, transbronchial biopsy, recurrent arrhythmia, lung transplant, vitamin K antagonists, pulmonary arterial hypertension, atrial tachycardia, GRIPHON trial, Cox-Maze procedure, morbidity, balloon pulmonary angioplasty, baseline lung allograft dysfunction, gene expression, atrial fibrillation, artificial intelligence, persistent atrial fibrillation, pulmonary angiogram, pulmonary function, chronic thromboembolic pulmonary hypertension, catheter ablation.
About
Concise summaries of cardiovascular research for professionals.
Subscribe • Share • FollowThe post AI Ablation Cuts Persistent AF Recurrence 11/17/25 first appeared on Cardiology Today.
In God we trust